奥拉帕尼
PARP抑制剂
癌症研究
PTEN公司
子宫内膜癌
拓扑异构酶抑制剂
基因敲除
合成致死
Wnt信号通路
DNA损伤
雷达51
细胞毒性
癌症
同源重组
聚ADP核糖聚合酶
医学
DNA修复
化学
PI3K/AKT/mTOR通路
细胞生长
癌细胞
药理学
细胞
生物
细胞凋亡
细胞培养
作者
Sung Wan Kang,Hye Rim Eum,Ji‐Young Lee,M. G. Lee,Yong‐Man Kim,Tae Won Kim,Shin‐Wha Lee
摘要
Endometrial cancer (EC) incidence continues to rise, underscoring the need for effective therapies beyond BRCA-mutant disease. Although PTEN loss, a frequent alteration in EC, has been implicated in impaired homologous recombination and increased sensitivity to PARP inhibitors, responses to PARP inhibitor monotherapy remain variable and are often limited by resistance mechanisms in PTEN-deficient tumours. Here, we show that the dual PARP/tankyrase (TNKS) inhibitor JPI-547 exerts potent antitumor activity, particularly in PTEN-deficient Ishikawa tumours. In vitro, JPI-547 and olaparib more effectively reduced cell survival in PTEN-deficient cells, and combined treatment with olaparib and the TNKS inhibitor XAV-939 induced synergistic cytotoxicity with elevated DNA double-strand breaks. Dual PARP/TNKS inhibition did not further suppress RAD51 but modulated non-homologous end joining and attenuated Wnt/β-catenin signalling in a PTEN-dependent manner. PTEN knockdown further showed enhanced vulnerability to combined targeting. These findings show that JPI-547 enhances antitumor efficacy in PTEN-deficient EC by disrupting DNA repair pathways and Wnt signalling, supporting dual PARP/TNKS inhibition as a potential therapeutic strategy and providing a rationale for further clinical evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI